NCT06577363 A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
| NCT ID | NCT06577363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Cytomegalovirus (CMV) |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-08-28 |
| Primary Completion | 2031-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-08-28 with a primary completion date of 2031-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation). The main aim of the study is to check if treatment with Maribavir can protect Japanese people against CMV infection, and to check side effect from the study treatment. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with CMV infection will take Maribavir tablets according to their clinic's standard practice. The study doctors will check for side effects from Maribavir tablets for 27 weeks.
Eligibility Criteria
Inclusion Criteria: \- All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation). Exclusion Criteria: \- None
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT06577363 clinical trial?
This trial is open to participants of all sexes, studying Cytomegalovirus (CMV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06577363 currently recruiting?
Yes, NCT06577363 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT06577363 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT06577363 clinical trial?
NCT06577363 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 250 participants.